Gasparini M, Priori S, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S (2003). “Flecainide test in Brugada syndrome: a reproducible but risky tool”. Pacing Clin Electrophysiol26 (1 Pt 2): 338–41. doi:10.1046/j.1460-9592.2003.00045.x. PMID12687841.
Padrini R, Piovan D, Busa M, al-Bunni M, Maiolino P, Ferrari M (1993). “Pharmacodynamic variability of flecainide assessed by QRS changes”. Clin Pharmacol Ther53 (1): 59–64. doi:10.1038/clpt.1993.9. PMID8422742.
Haefeli W, Bargetzi M, Follath F, Meyer U (1990). “Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo”. J Cardiovasc Pharmacol15 (5): 776–9. doi:10.1097/00005344-199005000-00013. PMID1692938.
Santinelli V, Arnese M, Oppo I, Matarazzi C, Maione S, Palma M, Giunta A (1993). “Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function”. Chest103 (4): 1068–73. doi:10.1378/chest.103.4.1068. PMID8131440.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989). “Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.”. N Engl J Med.321 (6): 406–412. doi:10.1056/NEJM198908103210629. PMID2473403.
Ohki R, Takahashi M, Mizuno O, Fujikawa H, Mitsuhashi T, Katsuki T, Ikeda U, Shimada K (2001). “Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia”. Pacing Clin Electrophysiol24 (1): 119–21. doi:10.1046/j.1460-9592.2001.00119.x. PMID11227957.
Morganroth J (1992). “Early and late proarrhythmia from antiarrhythmic drug therapy”. Cardiovasc Drugs Ther6 (1): 11–4. doi:10.1007/BF00050910. PMID1533532.
Fornieles-Pérez H, Montoya-García M, Levine P, Sanz O (2002). “Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate”. Pacing Clin Electrophysiol25 (5): 871–2. doi:10.1046/j.1460-9592.2002.00871.x. PMID12049386.
Winkelmann B, Leinberger H (1987). “Life-threatening flecainide toxicity. A pharmacodynamic approach”. Annals of Internal Medicine106 (6): 807–14. doi:10.7326/0003-4819-106-6-807. PMID3107447.
Yasui R, Culclasure T, Kaufman D, Freed C (1997). “Flecainide overdose: is cardiopulmonary support the treatment?”. Annals of Emergency Medicine29 (5): 680–2. doi:10.1016/S0196-0644(97)70257-9. PMID9140253.
P Camus, A Fanton, P Bonniaud, C Camus et al. "Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301–326 doi:10.1159/000079633PMID15316202
S Pesenti, D Lauque, G Daste, V Boulay et al. "Diffuse Infiltrative Lung Disease Associated with Flecainide. Respiration 2002; 69:182–185 doi:10.1159/000056325PMID11961436
Sakurada H, Hiyoshi Y, Tejima T, Yanase O, Tokuyasu Y, Watanabe K, Motomiya T, Sugiura M, Hiraoka M (1990). “[Effects of oral flecainide treatment of refractory tachyarrhythmias]”. Kokyu to Junkan38 (5): 471–6. PMID2115193.
Echt D, Liebson P, Mitchell L, Peters R, Obias-Manno D, Barker A, Arensberg D, Baker A, Friedman L, Greene H (1991). “Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial”. N Engl J Med324 (12): 781–8. doi:10.1056/NEJM199103213241201. PMID1900101.
Gasparini M, Priori S, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S (2003). “Flecainide test in Brugada syndrome: a reproducible but risky tool”. Pacing Clin Electrophysiol26 (1 Pt 2): 338–41. doi:10.1046/j.1460-9592.2003.00045.x. PMID12687841.
Katristis D, Rowland E, O'Nunain S, Shakespeare C, Poloniecki J, Camm A (1995). “Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle Implications for possible antiarrhythmic and proarrhythmic mechanisms”. Eu Heart J16 (1): 1930–1935. PMID8682029.
Wang Z, Fermini B, Nattel S (1993). “Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue”. J Pharmacol Exp Ther267 (2): 575–81. PMID8246130.
Smith G (1985). “Flecainide: a new class Ic antidysrhythmic”. Drug Intell Clin Pharm19 (10): 703–7. PMID3902429.
Padrini R, Piovan D, Busa M, al-Bunni M, Maiolino P, Ferrari M (1993). “Pharmacodynamic variability of flecainide assessed by QRS changes”. Clin Pharmacol Ther53 (1): 59–64. doi:10.1038/clpt.1993.9. PMID8422742.
Haefeli W, Bargetzi M, Follath F, Meyer U (1990). “Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo”. J Cardiovasc Pharmacol15 (5): 776–9. doi:10.1097/00005344-199005000-00013. PMID1692938.
Santinelli V, Arnese M, Oppo I, Matarazzi C, Maione S, Palma M, Giunta A (1993). “Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function”. Chest103 (4): 1068–73. doi:10.1378/chest.103.4.1068. PMID8131440.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989). “Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.”. N Engl J Med.321 (6): 406–412. doi:10.1056/NEJM198908103210629. PMID2473403.
Ohki R, Takahashi M, Mizuno O, Fujikawa H, Mitsuhashi T, Katsuki T, Ikeda U, Shimada K (2001). “Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia”. Pacing Clin Electrophysiol24 (1): 119–21. doi:10.1046/j.1460-9592.2001.00119.x. PMID11227957.
Morganroth J (1992). “Early and late proarrhythmia from antiarrhythmic drug therapy”. Cardiovasc Drugs Ther6 (1): 11–4. doi:10.1007/BF00050910. PMID1533532.
Fornieles-Pérez H, Montoya-García M, Levine P, Sanz O (2002). “Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate”. Pacing Clin Electrophysiol25 (5): 871–2. doi:10.1046/j.1460-9592.2002.00871.x. PMID12049386.
Winkelmann B, Leinberger H (1987). “Life-threatening flecainide toxicity. A pharmacodynamic approach”. Annals of Internal Medicine106 (6): 807–14. doi:10.7326/0003-4819-106-6-807. PMID3107447.
Corkeron M, van Heerden P, Newman S, Dusci L (1999). “Extracorporeal circulatory support in near-fatal flecainide overdose”. Anaesth Intensive Care27 (4): 405–8. PMID10470398.
Yasui R, Culclasure T, Kaufman D, Freed C (1997). “Flecainide overdose: is cardiopulmonary support the treatment?”. Annals of Emergency Medicine29 (5): 680–2. doi:10.1016/S0196-0644(97)70257-9. PMID9140253.
Ozkan M, Dweik RA, Ahmad M (September 2001). Drug-induced lung disease. 68. pp. 782–5, 789–95. PMID11563482.
P Camus, A Fanton, P Bonniaud, C Camus et al. "Interstitial lung disease induced by drugs and radiation. Respiration 2004; 71:301–326 doi:10.1159/000079633PMID15316202
S Pesenti, D Lauque, G Daste, V Boulay et al. "Diffuse Infiltrative Lung Disease Associated with Flecainide. Respiration 2002; 69:182–185 doi:10.1159/000056325PMID11961436
Haas M, Pérault MC, Bonnefoy P, Rodeau F, Caron F (2001). [Interstitial pneumopathy due to flecainide]. 30. pp. 1062. PMID11471279.
Robain A, Perchet H, Fuhrman C (February 2000). Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. 55. pp. 45–7. PMID10707759.
